Company profile
Opus Genetics, Inc.
NASDAQ: IRD · Healthcare · Biotechnology
PublicHQ Durham, MICIK 0001228627Reports USD
#587 of 1,417 Healthcare companies by revenue71st-percentile growth
EA Score
39DFH 31DQ 51GM 32SS 56
v0.1 · 65/100 weight · provisional
↑ market scale, revenue growth (YoY) · ↓ growth stability, return on equity
Methodology →Revenue TTM
$9.9M
Rev growth YoY (TTM)
-36.1%
Net income (FY)
-$49.6M
Employees
28
as of 2026-08-12
Market cap
$320.4M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$14.2M$14.2M2025
Net income-$49.6M-$49.6M2025
Operating income-$38.6M-$38.6M2025
Total assets$50.2M$50.2M2025
Liabilities$34.9M$34.9M2025
Equity$15.3M$15.3M2025
Revenue trend
FY2013 – FY2025 · USD
FY13
FY19
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Opus Genetics, Inc.’s revenue?
Opus Genetics, Inc. booked $14.2M in FY2025 revenue, growing 29% year over year — faster than most Healthcare companies we track, at a -349.3% net margin.
Peers · Healthcare
Lineage Cell Therapeutics, Inc.56CSunniva Inc.——Urologix, Inc.——Arbutus Biopharma Corp61CHealthcare Triangle, Inc.40DPyxis Oncology, Inc.28DKey facts
CEOGeorge Magrath
SectorHealthcare
IndustryBiotechnology
HeadquartersDurham, MI
ExchangeNASDAQ: IRD
Employees28
IPO date2015-01-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.